Genscript Biotech Corporation
1548
株式のランク
#2099
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
株価
$4.37
時価総額
$9.84B
変化（1日）
2.30%
変化（1年）
109.57%
国
HK
取引 Genscript Biotech Corporation (1548)
カテゴリー
Healthcare
Genscript Biotech Corporation（1548）のP/E比率
October 2026 時点のP/E比率 TTM -13.63
Genscript Biotech Corporation の最新の財務報告および株価によると、現在の P/E (TTM) は -13.63 です。2023 年末時点での P/E は -53.79 でした。
Genscript Biotech Corporation の P/E 比率の履歴（2013 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -13.63 | -1,565.67% |
| 2024 | 0.93 | -101.73% |
| 2023 | -53.79 | 82.95% |
| 2022 | -29.40 | 17.43% |
| 2021 | -25.04 | 86.25% |
| 2020 | -13.44 | -69.05% |
| 2019 | -43.43 | -138.14% |
| 2018 | 113.88 | -35.88% |
| 2017 | 177.59 | 484.44% |
| 2016 | 30.39 | 161.99% |
| 2015 | 11.60 | -65.24% |
| 2014 | 33.37 | -26.47% |
| 2013 | 45.38 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -311.15% |
US
|
|
| -28.36 | 108.05% |
US
|
|
| -24.57 | 80.23% |
AU
|
|
| 30.33 | -322.51% |
NL
|
|
| - | - |
CH
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。